Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/335939

Lähdeviite

Januszewski , A S , Chen , D , Scott , R S , O'Connell , R L , Aryal , N R , Sullivan , D R , Watts , G F , Taskinen , M-R , Barter , P J , Best , J D , Simes , R J , Keech , A C & Jenkins , A J 2021 , ' Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes ' , Scientific Reports , vol. 11 , no. 1 , 18708 . https://doi.org/10.1038/s41598-021-98064-y

Julkaisun nimi: Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
Tekijä: Januszewski, Andrzej S.; Chen, David; Scott, Russell S.; O'Connell, Rachel L.; Aryal, Nanda R.; Sullivan, David R.; Watts, Gerald F.; Taskinen, Marja-Riitta; Barter, Philip J.; Best, James D.; Simes, R. John; Keech, Anthony C.; Jenkins, Alicia J.
Tekijän organisaatio: Clinicum
Marja-Riitta Taskinen Research Group
HUS Heart and Lung Center
Department of Medicine
CAMM - Research Program for Clinical and Molecular Metabolism
Research Programs Unit
Päiväys: 2021-09-21
Kieli: eng
Sivumäärä: 12
Kuuluu julkaisusarjaan: Scientific Reports
ISSN: 2045-2322
DOI-tunniste: https://doi.org/10.1038/s41598-021-98064-y
URI: http://hdl.handle.net/10138/335939
Tiivistelmä: People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04-0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p
Avainsanat: GLYCATION END-PRODUCTS
AGE-PEPTIDES
FLUORESCENCE
SERUM
ACCUMULATION
ENDPRODUCTS
RETINOPATHY
MELLITUS
EVENTS
PEOPLE
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
s41598_021_98064_y.pdf 1.799MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot